Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Novartis Foundation Symposium|July 30, 2005
HERG channel traffickingEckhard Ficker, Adrienne Dennis, Yuri Kuryshev, et al.Molecular Pharmacology|December 10, 2020
Characterization of Vixotrigine, a Broad-Spectrum Voltage-Gated Sodium Channel BlockerChristopher A Hinckley, Yuri Kuryshev, Alissende Sers, et al.Proceedings of the National Academy of Sciences of the United States of America|December 5, 2020
Development and validation of a potent and specific inhibitor for the CLC-2 chloride channelAnna K Koster, Austin L Reese, Yuri Kuryshev, et al.Clinical Pharmacology and Therapeutics|August 29, 2018
Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA InitiativeZhihua Li, Bradley J Ridder, Xiaomei Han, et al.Clinical and Translational Science|February 23, 2021
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19Annie Delaunois, Matthew Abernathy, Warren D Anderson, et al.Journal of Pharmacological and Toxicological Methods|June 24, 2020
A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA modelXiaomei Han, Mohammadreza Samieegohar, Bradley J Ridder, et al.Toxicology and Applied Pharmacology|March 27, 2020
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigmBradley J Ridder, Derek J Leishman, Matthew Bridgland-Taylor, et al.Pageof 1